Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Autophagy, Informa UK Limited, Vol. 12, No. 1 ( 2016-01-02), p. 1-222
    Type of Medium: Online Resource
    ISSN: 1554-8627 , 1554-8635
    Language: English
    Publisher: Informa UK Limited
    Publication Date: 2016
    detail.hit.zdb_id: 2262043-6
    SSG: 12
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 83, No. 7_Supplement ( 2023-04-04), p. 2245-2245
    Abstract: This study aimed at unravelling whether WDLPS undergo a progressive evolution to DDLPS through analyzing the transcriptomic profile of retroperitoneal liposarcoma. In a contemporary retrospective series of primary retroperitoneal DDLPS and WDLPS (N=107), we sampled paired DD/WD/normal fat (NF) components of DDLPS and paired WD/NF components of WDLPS. RNA-Seq data was normalized using the trimmed mean of M-value (TMM) algorithm, heteroscedasticity was removed, and differential expression analysis (DEA) performed. Gene sets enrichment analysis (GSEA) evaluated enrichment in biological hallmarks and was performed to overcome FDR correction of DEA and evaluate the ensemble. FDR threshold 0.05 was considered for significance. Marked transcriptional changes exist among paired components of DDLPS (DD, WD, NF) or WDLPS (WD, NF). Although DEA did not show significant changes between WD and NF components of DDLPS and WDLPS, GSEA analysis highlighted deregulation in hallmarks. An upregulation of G2M checkpoint and mitotic spindle gene sets was observed when WD components of DDLPS was compared to WDLPS and progressively increase in the DD component. Some targetable genes from the leading edge of these pathways (PLK1, AURKA, and EZH2) as well as the primary oncogenic drivers (MDM2, CDK4, and HMGA2) of liposarcoma were functionally validated with targeted agents in cell lines of DDLPS and WDLPS, supporting findings of transcriptomic analysis. We also observed that adipogenesis, fatty acid metabolism, cholesterol homeostasis, oxidative phosphorylation, and peroxisome gene sets were down-regulated in the DD component, while glycolysis was upregulated compared to WD components. When NF were compared with their paired tumor components, G2M checkpoint and mitotic spindle gene sets did not differ between DDLPS and WDLPS, suggesting these two hallmarks as tumor-specific. NF of patients with DDLPS demonstrated higher expression of adipogenesis, and other pathways related to metabolism suggesting its metabolic activation compared to NF of patients with WDLPS. In conclusion, changes distinguishing WDLPS/DDLPS early at the WD stage and progressively increasing in the DD component of DDLPS supported the hypothesis of an orderly progression from WDLPS to DDLPS and represent a source of additional therapeutic targets. Citation Format: Sandro Pasquali, Stefano Percio, Dario Callegaro, Silvia Martini, Alessia Beretta, Alessia Bertolotti, Silvia Brich, Paola Collini, Marta Barisella, Loris De Cecco, Viviana Vallacchi, Silvia Stacchiotti, Matteo Benelli, Alessandro Gronchi, Nadia Zaffaroni. The transcriptomic profile of retroperitoneal primary well differentiated liposarcoma (WDLPS) and well differentiated (WD)/dedifferentiated (DD) components of DD liposarcoma (DDLPS) reveals the progression from WDLPS to DDLPS [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2245.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2023
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), Vol. 13, No. 1 ( 2014-01-01), p. 249-259
    Abstract: Patients with localized high-risk soft tissue sarcomas (STS) of the limbs and trunk wall still have a considerable metastatic recurrence rate of more than 50%, in spite of adjuvant chemotherapy. This drug-ceiling effect of chemotherapy in sarcoma setting could be explained, at least partially, by multidrug resistance (MDR) mechanisms. The aim of this study was to ascertain whether mRNA and protein expression of ABCB1 (P-glycoprotein), ABCC1 (MRP1), and GSTA1 (glutathione S-transferase pi) was prognostic in localized high-risk STS. Immunohistochemistry and reverse transcriptase-PCR studies were performed from biopsies at the time of diagnosis. Patients of this series were prospectively enrolled into a phase III trial that compared three versus five cycles of epirubicin plus ifosfamide. The series of 102 patients found 41 events of recurrence and 37 of death with a median follow-up of 68 months. In univariate analysis, variables with a statistically significant relationship with relapse-free survival (RFS) were: MRP1 expression (5-year RFS rate of 23% in positive cases and 63% in negative cases, P = 0.029), histology (5-year RFS rate of 74% in undifferentiated pleomorphic sarcoma and 43% in synovial sarcoma, P = 0.028), and ABCC1 expression (5-year RFS rate of 33% in overexpression and 65% in downregulation, P = 0.012). Combined ABCC1/MRP1 was the only independent prognostic factor for both RFS (HR = 2.704, P = 0.005) and overall survival (HR = 2.208, P = 0.029). ABCC1/MRP1 expression shows robust prognostic relevance in patients with localized high-risk STS treated with anthracycline-based chemotherapy, which is the standard front line treatment in STS. This finding deserves attention as it points to a new targetable protein in STS. Mol Cancer Ther; 13(1); 249–59. ©2013 AACR.
    Type of Medium: Online Resource
    ISSN: 1535-7163 , 1538-8514
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2062135-8
    SSG: 12
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    In: Modern Pathology, Elsevier BV, Vol. 33, No. 2 ( 2020-02), p. 217-227
    Type of Medium: Online Resource
    ISSN: 0893-3952
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2020
    detail.hit.zdb_id: 2041318-X
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, No. 16_suppl ( 2022-06-01), p. 11566-11566
    Abstract: 11566 Background: EHE is an ultra-rare sarcoma marked by two specific fusions, WWTR1-CAMTA1 (̃90%) and YAP1-TFE3 (̃10%). The clinical course of EHE ranges from indolent to highly aggressive, often associated with systemic paraneoplastic symptoms. Molecular predictors of clinical outcome are unknown. While surgery is the mainstay of treatment in the localized setting, management of advanced disease is challenging due to the rarity and poor sensitivity to conventional chemotherapy. This hampers the conduct of large prospective clinical trials. We report herein the first available EHE PDX (developed at the Istituto Nazionale Tumori, Milan, Italy) (INT), to assess the activity of old and new anticancer agents in EHE and inform future clinical studies. We also report on the preliminary results of a prospective observational study, ongoing in collaboration with The EHE Rare Cancer Charity (UK) and The EHE Foundation (US) aimed at identifying prognostic factors. Methods: A PDX of EHE in SCID mice was generated at INT from a patient (pt) suffering with the aggressive clinical variant, presenting with systemic symptoms. The PDX fully reproduces the originating clinical tumor in terms of morphology, biology ( WWTR1- CAMTA1 positive), overall transcriptomic profile. 2D (monolayer) and 3D (sferoids) cell cultures were established following PDX disaggregation. We have started assessing the comparative activity of currently available drugs (doxorubicin, sirolimus), while the efficacy of novel agents is undergoing. In parallel, we analyzed the presence of a selection of inflammatory cytokines in prospectively collected blood samples from EHE pts who entered an international observational study and we looked at their presence and modulation in the PDX model. Results: PDX experiments showed almost negligible activity of doxorubicin while sirolimus induced an 80% tumor volume inhibition. Biochemical analysis in tumors explanted from sirolimus-treated mice confirmed the down-regulation of mTOR downstream signaling. Among all cytokines, Growth and Differentiation Factor-15 (GDF-15) was found significantly over-expressed in serum of EHE pts (n = 23), particularly those with the most aggressive clinical variant, compared to healthy subjects (n = 23; p 〈 0.01). Consistently, EHE PDX and cell culture were found to release in the blood/culture medium GDF-15. Sirolimus was found to down-regulate GDF-15 release in both in vivo and in vitro EHE models. Conclusions: Our preliminary results indicate that this EHE PDX model is suitable i) for comparatively assessing the activity of anticancer drugs, and ii) for identifying and pre-clinically validating novel biomarkers. The role of GDF-15 in EHE progression deserves further investigation.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2022
    detail.hit.zdb_id: 2005181-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    In: Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), Vol. 22, No. 12_Supplement ( 2023-12-01), p. B096-B096
    Abstract: Introduction: Trabectedin or selinexor as single agent showed limited effectiveness in patients with metastatic DDLPS in clinical trials. We conducted a preclinical study on two patient-derived xenografts (PDXs) of DDLPS to test the activity of combined and sequential treatment with selinexor and trabectedin or lurbinectedin, following evidence of clinical benefit from a rechallenge to trabectedin after selinexor in two patients with metastatic DDLPS. Methods: Two PDXs (LPS-BZ; LPS-NV) from two patients with primary localized DDLPS treated with surgery were established in SCID mice. These models represented the DD component of DDLPS and were histomorphologically and molecularly (by FISH and RNAseq) characterized for consistency with the originating clinical tumors. Antitumor activity of single-agent selinexor and either trabectedin or lurbinectedin as well as of the selinexor-trabectedin sequence and both selinexor-lurbinectedin sequence and combination was assessed. Drug activity was evaluated as maximum tumor volume inhibition percentage (max TVI%). Results: The anti-cancer activity of a re-challenge to trabectedin following treatment with selinexor, which was observed in two patients, let to the design of in-vivo experiments on PDXs of DDLPS to investigate the activity of a sequential treatment with selinexor plus trabectedin/luribinectedin or their combination. The histomorphological and molecular characteristics of PDXs of DDLPS (LPS-BZ and LPS-NV) were confirmed to reproduce the clinical tumor. In the PDX model (LPS-BZ) with the faster growth rate (doubling time: 5 days), the sequence of selinexor followed by trabectedin was more effective (max TVI 61%) than each single-agent (maxTVI 46% and 33% for selinexor and trabectedin, respectively). A further experiment was conducted in a PDX model (LPS-NV) characterized by a slower growth rate (doubling time: 12 days)  and results consistently showed a greater activity for the selinexor and trabectedin sequence (mTVI 73%) compared to selinexor (mTVI 53%) or trabectedin (mTVI 35%) alone. Finally, we tested lurbinectedin instead of trabectedin in the LPS-NV PDX model. The sequence selinexor and lurbinectedin (mTVI 81%) or their combination (mTVI 74%) showed a greater anti-tumor effect compared to single agent selinexor (mTVI 65%) or lurbinectedin (mTVI 24%). RNA-seq analysis of control and treated tumors is ongoing to investigate the determinants of the positive interactions between trabectedin/lurbinectedin and selinexor as a function of treatment schedule. Conclusion: The combination of selinexor with either trabectedin or lurbinectedin in DDLPS showed anti-tumor activity. Further analyses are ongoing to investigate the mechanisms underpinning the interaction of these drugs. Citation Format: Sandro Pasquali, Noemi Arrighetti, Valentina Zuco, Cesare Soffientini, Monica Tortoreto, Silvia Brich, Marta Barisella, Paola Collini, Chiara Fabbroni, Sara Cingarlini, Alessandro Gronchi, Silvia Stacchiotti, Roberta Sanfilippo, Nadia Zaffaroni. A comparative assessment of selinexor with trabectedin or lurbinectedin in patient-derived xenografts (PDX) of dedifferentiated liposarcoma (DDLPS) highlights the effectiveness of their sequential or concomitant combination [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr B096.
    Type of Medium: Online Resource
    ISSN: 1538-8514
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2023
    detail.hit.zdb_id: 2062135-8
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2023
    In:  Molecular Cancer Therapeutics Vol. 22, No. 12_Supplement ( 2023-12-01), p. B011-B011
    In: Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), Vol. 22, No. 12_Supplement ( 2023-12-01), p. B011-B011
    Abstract:  Background: Epithelioid hemangioendothelioma (EHE) is an ultra-rare vascular sarcoma marked by two fusions - TAZ-CAMTA1 (~90%) and YAP-TFE3 (~10%) - that lead to Hippo-pathway activation. EHE clinical behavior ranges from indolent disease to highly aggressive presentation, but no biomarkers are known to predict the clinical outcome at disease onset. Conventional chemotherapy has limited effectiveness in advanced EHE patients and new treatment options are needed, as well as novel biomarkers of aggressiveness. We exploited i) two independent patient series to identify circulating biomarkers of EHE aggressiveness; ii) an EHE patient-derived xenograft (PDX) model and the derived cell line to investigate the effectiveness of sirolimus, one of the antitumor agents considered more effective in EHE. Methods: Two independent patient series were exploited to test the association between Growth/differentiation factor 15 (GDF-15) serum levels and EHE aggressiveness. A PDX model was generated from a patient with advanced EHE and showed consistency with the original tumor in terms of histomorphology, presence of the TAZ-CAMTA1 fusion and transcriptomic profile. This model - the only human EHE model available worldwide - has been used to generate a corresponding cell line. GDF-15 release from EHE cells and PDX was quantified by ELISA. Drugs cytotoxicity on EHE cells was assessed through cell counting and TUNEL assay. Western blotting was used to investigate sirolimus effects on EHE cells. Results: Analyses of blood samples from two independent patient series showed a statistically significant correlation between GDF-15 levels and EHE aggressiveness. ELISA on the blood of EHE-carrying mice and EHE cell culture medium revealed that GDF-15 is released by tumor cells. Sirolimus induced a significantly higher tumor growth inhibition (80%) compared to doxorubicin, whose activity was almost negligible in the EHE PDX. Also in EHE cells, sirolimus showed a lower IC50  (0.01µM versus 0.1µM) and a greater apoptotic response (TUNEL-positive cells: 20% vs 10%) than doxorubicin. Interestingly, sirolimus reduced GDF-15 expression/release in both in vivo and in vitro EHE models by reducing the expression of the GDF-15 transcription factor ATF4, as a consequence of the drug-induced inhibition of phosphorylation/activation of 4E-BP1, which is involved in the regulation of ATF4 translation. Conclusions: Results from this study indicate that: i) GDF-15 is a novel biomarker of EHE aggressiveness; ii) sirolimus is more effective than doxorubicin in our experimental model, supporting the suitability of the model for comparative studies on the activity of anticancer drugs for EHE treatment. Moreover, the notion that sirolimus inhibits the release of GDF-15 from EHE would suggest the relevance of this cytokine as a biomarker for monitoring sirolimus activity in patients. Further investigations are ongoing to clarify the role of GDF-15 in EHE progression. Citation Format: Alessia Beretta, Valentina Zuco, Silvia Martini, Anna Maria Frezza, Sandro Pasquali, Silvia Stacchiotti, Nadia Zaffaroni. GDF-15 is a biomarker of aggressiveness in epithelioid hemangioendothelioma and is down-regulated by sirolimus through ATF4 suppression [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr B01 1.
    Type of Medium: Online Resource
    ISSN: 1538-8514
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2023
    detail.hit.zdb_id: 2062135-8
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    In: Journal of Experimental & Clinical Cancer Research, Springer Science and Business Media LLC, Vol. 40, No. 1 ( 2021-12)
    Abstract: Dedifferentiated liposarcoma (DDLPS), a tumor that lacks effective treatment strategies and is associated with poor outcomes, expresses amplified MDM2 in the presence of wild-type p53. MDM2 ubiquitination of p53 facilitates its XPO1-mediated nuclear export, thus limiting p53 tumor suppressor functions. Consequently, nuclear export is a rational target in DDLPS. We directly compared the antitumor activity of the first-in class XPO1 inhibitor selinexor and doxorubicin, the standard front-line therapy in sarcomas, in DDLPS patient-derived xenografts (PDXs) and primary cell lines. Methods Drug activity was assessed in three PDXs (and two corresponding cell lines) established from the dedifferentiated component of primary untreated retroperitoneal DDLPS with myogenic ( N  = 2) and rhabdomyoblastic ( N  = 1) differentiation from patients who underwent surgery. These models were marked by amplification of MDM2 , CDK4 and HMGA2 genes. Results Selinexor was moderately active in the three PDXs but achieved greater tumor response compared to doxorubicin (maximum tumor volume inhibition: 46–80 % vs. 37–60 %). The PDX harboring rhabdomyoblastic dedifferentiation showed the highest sensitivity to both agents. PDX response to selinexor and doxorubicin was not associated with the extent of MDM2 and CDK4 gene amplification. Interestingly, the most chemosensitive PDX model showed the lowest extent of HMGA2 amplification. Selinexor was also more efficient than doxorubicinin in inducing an apoptotic response in PDXs and cell lines. Consistently, an increased nuclear accumulation of p53 was seen in all selinexor-treated models. In addition, a time-dependent decrease of survivin expression, with an almost complete abrogation of the cytoplasmic anti-apoptotic pool of this protein, was observed as a consequence of the decreased acetylation/activation of STAT3 and the increased ubiquitination of nuclear survivin. Conclusions Selinexor showed a moderate antitumor activity in three DDLPS PDXs, which was, however, consistently higher than doxorubicin across all different models regardless the extent of MDM2 amplification and the histological differentiation. The depletion of survivin protein seems to significantly contribute to the induction of apoptosis through which selinexor exerts its antitumor activity.
    Type of Medium: Online Resource
    ISSN: 1756-9966
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2021
    detail.hit.zdb_id: 2430698-8
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, No. 16_suppl ( 2022-06-01), p. e23520-e23520
    Abstract: e23520 Background: Retroperitoneal DDLPS is an aggressive tumor characterized by a WD component, morphologically similar to a WDLPS, and a DD component that drives patient prognosis. We aimed at unraveling whether WDLPS and DDLPS are distinct entities or entail a progressive evolution from WDLPS to DDLPS through a transcriptomic analysis. Methods: A transcriptomic analysis was performed in a retrospective series of 107 patients with primary retroperitoneal WDLPS (N = 68, 63.5%) or DDLPS (N = 39, 36.5%) who underwent surgery (2011-15). Paired DD, WD, and normal fat (NF) components were sampled in DDLPS, while paired WD and NF components were sampled in WDLPS. RNA-Seq data were normalized according to the trimmed mean of M-value (TMM) algorithm and differential expression was evaluated with the voom method implemented into the edgeR package. Enrichment in hallmark gene sets from Molecular Signatures Database (MSigDB) was evaluated with gene sets enrichment analysis (GSEA), by using t-statistic as measure of ranking. A false discovery rate (FDR) adjusted p-value 〈 0.05 was considered for statistical significance. Results: Differential expression analysis revealed marked transcriptional changes within paired components of DDLPS (DD, WD, NF) and WDLPS (WD, NF). Changes of WD and NF components between WDLPS and DDLPS were not statistically significant. Gene sets were analyzed to evaluate the ensemble and overcome the FDR correction applied to single genes. Hallmarks deregulated in WD component of DDLPS compared to WDLPS were detected also in their paired DD component. Among them, G2M checkpoint and mitotic spindle were up-regulated, while adipogenesis, fatty acid metabolism, cholesterol homeostasis, oxidative phosphorylation, and peroxisome were down-regulated. These differences persisted also when NF components were compared with their paired WD component of DDLPS and WDLPS. G2M checkpoint and mitotic spindle gene sets did not differ between NF of DDLPS and NF of WDLPS, suggesting these two hallmarks as tumor-specific. Conversely, expression of adipogenesis, fatty acid metabolism, and oxidative phosphorylation was up-regulated together with other gene sets related to metabolism in NF of DDLPS. Tumor inflammation and interferon response were up-regulated in WD components compared to their paired NF components. Also, interferon response was down-regulated in WD component of DDLPS compared to WDLPS, and inflammation was down-regulated in DD component compared to both WD components. Conclusions: Transcriptomic changes that distinguished WDLPS and WD component of DDLPS increased progressively also in the paired DD component of DDLPS, supporting the hypothesis of a progression from WDLPS to DDLPS in some liposarcomas. Changes observed in NF may suggest a paracrine effect sustaining tumor dedifferentiation.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2022
    detail.hit.zdb_id: 2005181-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    In: ESMO Open, Elsevier BV, Vol. 5, No. 1 ( 2020), p. e000604-
    Type of Medium: Online Resource
    ISSN: 2059-7029
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2020
    detail.hit.zdb_id: 2844985-X
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages